Dr. Gregory Weinhoff is Chief Business Officer of Centessa Pharmaceuticals. Before taking on the role of CBO, Greg served as Chief Financial Officer of Centessa from March 2021 to June 2024. Previously, Greg was a Co-Founder and Chief Financial and Chief Business Officer at Arvelle Therapeutics BV. In that role, he was responsible for sourcing cenobamate, a novel anti-seizure medicine with best-in-class efficacy, negotiating the license with SK Biopharmaceuticals for European rights, and raising a $207.8M start-up financing, which was one of the largest start-up financings for a European biopharma. Greg played a key role in preparing the Arvelle organization for commercialization and drove the strategic sale process, which resulted in the $960M acquisition by Angelini Pharma.
Previously, Greg was Chief Financial Officer at Axovant Sciences, Inc., where he oversaw finance, accounting, investor relations and business development. At Axovant, he was the principal financial and accounting officer for SEC purposes and was responsible for three public financings, a private placement, and a venture debt financing.
Before becoming Chief Financial Officer of Axovant, Greg spent 15 years as an early-stage healthcare venture capitalist at CHL Medical Partners. He was the founding chief executive officer and sole Series A investor in Amicus Therapeutics where he remained a board member and member of the audit committee through its IPO in 2009. Prior to graduate school, Greg was a financial analyst in Morgan Stanley & Co.’s healthcare corporate finance group.
Greg holds an MD degree from Harvard Medical School, an MBA from Harvard Business School, and an AB in economics from Harvard College.
What is Gregory M. Weinhoff's net worth?
The estimated net worth of Gregory M. Weinhoff is at least $3.61 million as of July 25th, 2025. Dr. Weinhoff owns 122,279 shares of Centessa Pharmaceuticals stock worth more than $3,614,567 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Weinhoff may own. Additionally, Dr. Weinhoff receives an annual salary of $655,000.00 as Chief Business Officer at Centessa Pharmaceuticals. Learn More about Gregory M. Weinhoff's net worth.
How old is Gregory M. Weinhoff?
Dr. Weinhoff is currently 53 years old. There are 5 older executives and no younger executives at Centessa Pharmaceuticals. The oldest executive at Centessa Pharmaceuticals is Dr. David M. Chao Ph.D., Chief Administrative Officer, who is 56 years old. Learn More on Gregory M. Weinhoff's age.
What is Gregory M. Weinhoff's salary?
As the Chief Business Officer of Centessa Pharmaceuticals PLC Sponsored ADR, Dr. Weinhoff earns $655,000.00 per year. There are 2 executives that earn more than Dr. Weinhoff. The highest earning executive at Centessa Pharmaceuticals is Dr. Saurabh Saha M.D., Ph.D., CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Gregory M. Weinhoff's salary.
How do I contact Gregory M. Weinhoff?
Has Gregory M. Weinhoff been buying or selling shares of Centessa Pharmaceuticals?
Gregory M. Weinhoff has not been actively trading shares of Centessa Pharmaceuticals in the last ninety days. Most recently, Gregory M. Weinhoff sold 10,000 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $15.56, for a transaction totalling $155,600.00. Following the completion of the sale, the insider now directly owns 122,279 shares of the company's stock, valued at $1,902,661.24. Learn More on Gregory M. Weinhoff's trading history.
Who are Centessa Pharmaceuticals' active insiders?
Centessa Pharmaceuticals' insider roster includes Mario Accardi (President of the Orexin Program), Karen Anderson (Chief People Officer), Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), Arjun Goyal (Director), David Grainger (Insider), Iqbal Hussain (General Counsel and Corporate Secretary), Aaron Kantoff (Director), Harris Rotman (Senior Vice President, Regulatory Affairs), Saurabh Saha (CEO), Gregory Weinhoff (Chief Business Officer), and Antoine Yver (EVP). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?
In the last year, Centessa Pharmaceuticals insiders bought shares 2 times. They purchased a total of 462,585 shares worth more than $5,866,686.94. In the last year, insiders at the sold shares 45 times. They sold a total of 973,366 shares worth more than $16,763,018.36. The most recent insider tranaction occured on November, 12th when CTO Tia L Bush sold 40,000 shares worth more than $1,040,000.00. Insiders at Centessa Pharmaceuticals own 7.1% of the company.
Learn More about insider trades at Centessa Pharmaceuticals. Information on this page was last updated on 11/12/2025.
